Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.

Publication Year: 2023

DOI:
10.1039/d3tb02268d

PMCID:
PMC10718295

PMID:
37955203

Journal Information

Full Title: J Mater Chem B

Abbreviation: J Mater Chem B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Nanotechnology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest SPR, AO, CL, FYH, AS, KT, MN, AO, CFM and SPR are coinventors on a published patent application (WO2020128525) describing the presented polymers."

Evidence found in paper:

"The authors wish to thank the US National Institutes of Health (NIH) under grant number R01AI134091-01, for funding of this transatlantic collaboration. The authors also acknowledge the University of Liverpool Materials Innovation Factory for access to equipment, and the Centre of Excellence for Long-acting Therapeutics for access to analytical facilities. Manchester Organics Ltd are also acknowledged for the efficient scale up of compound 5 and the provision of high purity multi-gram samples."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025